- Home
- IMUX vs LODE Comparison
IMUX vs LODE Comparison
Compare IMUX & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- LODE
- Stock Information
- Founded
- IMUX 2016
- LODE 2008
- Country
- IMUX United States
- LODE United States
- Employees
- IMUX N/A
- LODE N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- LODE Major Chemicals
- Sector
- IMUX Health Care
- LODE Industrials
- Exchange
- IMUX Nasdaq
- LODE Nasdaq
- Market Cap
- IMUX 86.3M
- LODE 61.6M
- IPO Year
- IMUX N/A
- LODE N/A
- Fundamental
- Price
- IMUX $1.10
- LODE $2.42
- Analyst Decision
- IMUX Strong Buy
- LODE Buy
- Analyst Count
- IMUX 6
- LODE 1
- Target Price
- IMUX $12.67
- LODE $26.00
- AVG Volume (30 Days)
- IMUX 863.2K
- LODE 476.5K
- Earning Date
- IMUX 03-18-2025
- LODE 03-06-2025
- Dividend Yield
- IMUX N/A
- LODE N/A
- EPS Growth
- IMUX N/A
- LODE N/A
- EPS
- IMUX N/A
- LODE N/A
- Revenue
- IMUX N/A
- LODE $3,016,163.00
- Revenue This Year
- IMUX N/A
- LODE $69.41
- Revenue Next Year
- IMUX N/A
- LODE $64.66
- P/E Ratio
- IMUX N/A
- LODE N/A
- Revenue Growth
- IMUX N/A
- LODE 136.66
- 52 Week Low
- IMUX $0.92
- LODE $1.30
- 52 Week High
- IMUX $2.11
- LODE $10.10
- Technical
- Relative Strength Index (RSI)
- IMUX 49.81
- LODE 35.38
- Support Level
- IMUX $1.12
- LODE $2.32
- Resistance Level
- IMUX $1.22
- LODE $2.99
- Average True Range (ATR)
- IMUX 0.11
- LODE 0.34
- MACD
- IMUX -0.01
- LODE 0.00
- Stochastic Oscillator
- IMUX 25.64
- LODE 14.29
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.